OncoAlly hereditary cancer icon

OncoAlly® Hereditary Cancer Case Study

Variantyx. See more from the very first test.

Overview

Patient: 


Male in his mid 40’s

Clinical presentation:


History of bilateral carotid paraganglioma

Testing strategy:

Variantyx whole genome testing

Key finding:

Pathogenic 15.68 kb deletion in the SDHB gene

Clinical outcome:

Diagnosis established and family testing enabled

Why OncoAlly® was the right choice

Despite prior non-diagnostic multi-gene cancer panel + RNA analysis testing, a concern for hereditary cancer susceptibility remained due to the patient’s personal history of bilateral carotid paraganglioma and family history of lung, gastric and prostate cancer.

OncoAlly® was selected because it delivers the most comprehensive genomic insight from the start while:

  • Reducing time to diagnosis
  • Avoiding unnecessary testing
  • Supporting the highest standard of patient care

Diagnostic finding: Hereditary pheochromocytoma / paraganglioma syndrome 4

Variantyx OncoAlly® hereditary cancer testing identified a heterozygous, pathogenic 15.68 kb deletion that removes exon 1 of the SDHB gene.

The deletion is expected to result in loss of protein function.

Uniform data from WGS clearly shows the 15.68 kb single exon deletion.

Impact on clinical care

Surgery is likely to be recommended over observation as paragangliomas associated with germline SDHB variants are aggressive and more prone to metastasis. In addition, targeted follow-on screening of at-risk family members was enabled.

Variant spotlight: Single exon deletion

Detection challenges

Targeted tests are typically unable to detect deletions smaller than 500 bp, a size that individual exons often fall below. Furthermore, panel tests focus on coding regions only, ignoring intergenic and intronic sequences. This leads to critical coverage gaps that make it impossible to detect deletion breakpoints within these regions.

Why OncoAlly®

  • Has a detection range from 1 bp to whole chromosomal events, easily detecting single exon deletions of any size.
  • Sequences and analyzes both coding and non-coding regions, enabling breakpoint detection regardless of location.

The choice is in your hands. Choose Variantyx.

Talk with a Clinical Specialist